EPH156 Modelling Herpes Zosters Burden and Public Health Impact of Adjuvanted Recombinant Zoster Vaccine Among Adults Aged ≥50 Years Old in Seven Countries in Central and South America

Data on herpes zoster (HZ) burden are scarce in Latin America. In 2023, an adjuvanted recombinant zoster vaccine (RZV) launched in Argentina, Brazil, and Mexico. To estimate HZ burden and impact of vaccinating adults aged ≥50 years in Peru, Ecuador, and five Central American and Caribbean (CARICAM) countries (Panama, Guatemala, Dominican Republic, Costa Rica, Trinidad& Tobago), modelling analyses were conducted for each country.

Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: R. Han, A. Guzman-Holst, J. G ómez, L. Naranjo, T. Rosales, D. van Oorschot Source Type: research